Abstract 1028
Background
The best time to initiate concurrent chemoradioation (ChRT) with temozolamide after surgery in glioblastoma multiform (GBM) patients has not been clearly established. Our aim was to investigate whether survival is influenced by the time to ChRT in patients with different types of surgery.
Methods
We conducted a retrospective study of all the patients treated in our centre from January 2005 to December 2017, with a histological diagnosed GBM, which underwent surgery and completed concurrent ChRT with temozolamide. The time to ChRT was grouped in 4 quartiles, and early ChRT was defined as happening during the first quartile. Surgery type was divided into resection (R) and biopsy (B). Survival at 12 months (OS12m), median progression free survival (mPFS) and overall survival (mOS) were calculated. Other relevant clinical factors were also analyzed.
Results
From a total of 160 patients, 119 who completed ChRT were included. The median time to ChRT was 37 days, (Q1=26, Q2=37, Q3=45); 35 (30%) received early ChRT (≤26 days). Patients who underwent R were 101 (85%) and 18 (15%) B. The mean age was 62y, 94 patients (79%) had PS 0-1, MGMT methylation was positive in 23 (19%). There were no significant differences between groups regarding Age, PS and MGMT status; but more patients treated with B received early ChRT (31% vs 8%). The OS12m was shorter for patients who underwent R and received early vs no-early ChRT (35% vs 73%, p = 0.002). No differences in OS12m were found for B patients (0% vs 18%, p = 0.4) according to time to ChRT. For patients who received early ChRT, the mOS was similar despite surgery type (9.9, 95% CI 9.6 – 11 vs 12.9, 95% CI 6.5 – 19.3, p = 0.8, for R and B, respectively). But for patients who did not receive early ChRT, longer survival was achieved in the R vs B subgroup (16.2, 95%CI 14.1 – 17.8 vs 11.1, 95% CI 4.5 – 17.7, p = 0.024, for R and B, respectively) and resection type remained significant in the multivariate analysis (HR = 1.2, p = 0.02).
Conclusions
We have found that patients with GBM who underwent resection had a worse prognosis if they received early chemoradiation (≤ 26 days). No differences were found for biopsied patients. A no-early chemoradation approach for patients who underwent resection may be safe. Prospective studies are encouraged.
Clinical trial identification
Legal entity responsible for the study
Hospital de la Santa Creu i Sant Pau.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract